Company Description
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases.
Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy.
Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701.
The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017.
Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 159 |
| CEO | Dipal Doshi |
Contact Details
Address: One Design Center Place, Suite 17- 500 Boston, Massachusetts 02210 United States | |
| Phone | 857 520 9158 |
| Website | entradatx.com |
Stock Details
| Ticker Symbol | TRDA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001689375 |
| CUSIP Number | 29384C108 |
| ISIN Number | US29384C1080 |
| Employer ID | 81-3983399 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dipal Doshi | Chief Executive Officer and Director |
| Nathan J. Dowden | President and Chief Operating Officer |
| Dr. Natarajan Sethuraman Ph.D. | President of Research and Development |
| Kory James Wentworth CPA | Chief Financial Officer and Treasurer |
| Dr. Jared Cohen J.D., Ph.D. | General Counsel |
| Kerry Robert M.S. | Senior Vice President of People |
| Karla MacDonald | Chief Corporate Affairs Officer |
| Kevin Healy Ph.D. | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 144 | Filing |
| Nov 12, 2024 | 144 | Filing |
| Nov 5, 2024 | 10-Q | Quarterly Report |
| Nov 5, 2024 | 8-K | Current Report |
| Oct 16, 2024 | 144 | Filing |
| Sep 9, 2024 | 144 | Filing |
| Sep 6, 2024 | 144 | Filing |
| Aug 16, 2024 | 144 | Filing |
| Aug 13, 2024 | 10-Q | Quarterly Report |